The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Personalized treatments to manage post-transplantation outcomes in AML: insights from MORPHO
Charles Craddock, CBE, FRCP, FRCPath, University of Birmingham, Birmingham, UK, discusses the MORPHO trial (NCT02997202), where gilteritinib showed benefits in a measurable residual disease (MRD)-positive subgroup of patients with FLT3-mutated acute myeloid leukemia (AML) post-transplantation. Prof. Craddock highlights the need for further exploration of targeted maintenance therapies, including menin and IDH inhibitors. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
